Theramex in the news
Women's healthcare solutions and products
Tamtam found 20 recent articles about Theramex.
- HRT maker censured by regulators for ‘systemic failures’ that risked patient safety
Theramex has been censured by regulators for systemic compliance failures and outdated safety information regarding its HRT and women's health products.
- Theramex exits self-regulatory body after ‘systemic’ compliance failures
Theramex has opted out of the UK's pharmaceutical self-regulation program following systemic compliance failures and a public reprimand for misleading marketing.
- Individualisation of Menopausal Hormone Therapy and Its Impact on Long-term Health
Educational infographic on individualizing hormone therapy for menopause and its long-term health effects.
- UK marketing watchdog slams Theramex for 'wholly unacceptable' compliance failings
Theramex faced severe criticism from UK regulators for failing to update product safety information and maintain marketing compliance standards.
- Major HRT supplier sanctioned after whistleblowers raise concerns over patient safety
Theramex has been sanctioned by the ABPI after whistleblowers exposed outdated prescribing information and safety non-compliance for its HRT treatments.
- Theramex receives recommendation for YSELTY in Scotland
Theramex's YSELTY has been recommended by the Scottish Medicines Consortium for treating moderate to severe uterine fibroids, making it available on the NHS in Scotland.
- Theramex’s Eladynos recommended by NICE for post-menopausal bone disease
Theramex's Eladynos has been recommended by NICE for treating post-menopausal bone disease, offering a new option for patients at high risk of fracture in the UK.
- NICE supports Theramex’s Eladynos for post-menopause osteoporosis
Theramex's osteoporosis drug Eladynos received NICE recommendation for use in England to reduce fracture risk in post-menopausal women.
- Pharma deal could reduce choice and lead to higher prices for HRT treatments
The UK competition regulator warns that the acquisition of Viatris HRT products by Theramex could raise prices and limit healthcare choices.
- Theramex
Theramex provides specialty pharmaceutical products for women's health while scaling its impact through ESG-linked financing and improved patient access.
- Theramex enters into an exclusive licensing agreement with Radius Health Inc to commercialise ELADYNOS®
Theramex secured an exclusive licensing agreement with Radius Health Inc. to commercialise the osteoporosis treatment ELADYNOS® across multiple international markets.
- Bedell Cristin advises on sale of Theramex by CVC
Bedell Cristin advised the management team of Theramex, a women's health pharmaceuticals company, on its sale from CVC Capital Partners VI to Carlyle and PAI Partners.
- Latham Advises on CVC’s Sale of Theramex to PAI Partners and Carlyle
CVC Capital Partners sold women's health specialty pharmaceutical company Theramex to PAI Partners and Carlyle, with Latham & Watkins providing advisory services for the transaction.
- PE Today: CVC Exits Theramex, Estancia Invests in Financial Services
CVC Capital Partners is selling women's health company Theramex to Carlyle Group and PAI Partners for an estimated $1.4 billion, while Estancia Capital Partners is investing in a merger of R&T and TBS, and Freshfields is advising on financing for Waterland's acquisition of RUF Group brands.
- Carlyle, PAI Agree to Buy CVC’s Women’s Health Business Theramex
Carlyle and PAI acquired London-based women's health business Theramex from CVC for an estimated $1.4 billion.
- CVC Fund VI agrees exit of Theramex
Theramex, a global specialty pharmaceutical company focused on women's health, is being acquired by PAI Partners and Carlyle to drive international growth and product expansion.
- Carlyle, PAI Nearing $1.4 Billion Deal for CVC’s Theramex
Carlyle Group and PAI Partners are close to acquiring women's health business Theramex for $1.4 billion.
- International Women's Day sees Theramex reinforce its commitment to women's health
Theramex reinforces its commitment to women's health and partners with various organizations to support women on International Women's Day and throughout the year.
- Theramex to market Prolia biosimilar in Europe and Australia
Theramex signed an agreement with Enzene Biosciences Limited to market a denosumab biosimilar for osteoporosis treatment in Europe and Australia.
- Fred Hassan appointed chairman of Theramex
Fred Hassan was appointed chairman of Theramex, a new women's health company formed by CVC Capital Partners, with Anish Mehta as CEO.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Theramex?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies